Oppenheimer analyst Kevin DeGeeter maintained a Buy rating on Ionis Pharmaceuticals (NASDAQ:) on Tuesday, setting a price target of $63, which is approximately 40.12% above the present share price of $44.96.
DeGeeter expects Ionis Pharmaceuticals to post earnings per share (EPS) of -$2.44 for the first quarter of 2021.
The current consensus among 12 TipRanks analysts is for a Moderate Buy rating of shares in Ionis Pharmaceuticals, with an average price target of $57.2.
The analysts price targets range from a high of $86 to a low of $33.
In its latest earnings report, released on 12/31/2020, the company reported a quarterly revenue of $290.28 million and a net profit of -$22.64 million. The company’s market cap is $6.33 billion.
According to TipRanks.com, Oppenheimer analyst Kevin DeGeeter is currently ranked with 5 stars on a 0-5 stars ranking scale, with an average return of 50.9% and a 51.96% success rate.
Ionis Pharmaceuticals, Inc. engages in the development and commercialization of human therapeutic drugs using antisense technology. It operates through the Ionis Core and Akcea Therapeutics (NASDAQ:) segments. The Ionis Core segment exploits a novel drug discovery platform to generate a pipeline of drugs. The Akcea Therapeutics segment develops and commercializes drugs for cardiometabolic diseases. The company was founded by Stanley T. Crooke, David J. Ecker, Christopher K. Mirabelli and Brett P. Monia in 1989 and is headquartered in Carlsbad, CA.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.